Breast Cancer Clinical Trial
Official title:
Acupressure for Preventing Post-Operative Pain and Opioid Use Among Breast Cancer Patients Receiving Surgery
This study seeks to determine the feasibility of recruiting and training participants in self-acupressure, for women undergoing primary breast cancer surgery or delayed reconstruction surgery. The study seeks to determine also if self-acupressure is effective in reducing the need for opioids post-surgery and the effects on other life factors.
Chronic pain following breast cancer surgery is a significant problem for women. There are
over 3 million women in the United States living as breast cancer survivors. Sustained
post-surgical pain is one of the most troubling side-effects for these women and continues to
affect around 25-60% of breast cancer survivors, with approximately half classifying pain as
being moderate to severe. Chronic cancer-related pain is associated with increased fatigue,
depression, anxiety, sleep disruption, and decreased quality of life and function.
Acute pre- and post-operative pain are significant predictors of sustained pain following
breast cancer surgery, but are insufficiently managed. The etiology of persistent breast
cancer related pain following surgery is multifactorial and may be the direct effect of
cancer or cancer treatment (e.g. surgery). Known risk factors for this chronic pain include
younger age, higher body mass index, type of surgery (axillary lymph node dissection), and
presence of a mood disturbance. Cancer patients may develop pain from neurotoxicity from
adjuvant chemotherapy, and radiation may also play a role, and causes persistent pain in 13 -
26% of patients.
Two of the most significant factors that determine persistent pain following breast cancer
surgery are the degree of pre-surgical pain and acute post-surgical pain. Recent reports have
suggested that treatments aimed at reducing these factors may be effective at preventing the
development of chronic pain following breast cancer surgery. Existing pre-emptive treatments
to reduce this acute surgical pain include the use of nerve blocks and/or pharmacologic
agents such as opioids, NSAIDs, ketamine, and gabapentin. While some pharmacologic approaches
yield clinically meaningful reductions in post-operative pain in the research setting, there
remains controversy in the field. For example in breast surgery specifically, a recent
meta-analysis showed that thoracic paravertebral blocks have a statistically significant
effect on reducing chronic pain, but the effect was not clinically meaningful and was
associated with procedural risks such as vascular puncture.
In addition to the risk of developing pain following breast cancer surgery, women also report
increased acute and chronic surgical pain following breast reconstruction surgery. In one of
the first studies to examine pain post-reconstruction surgery, Wallace et al. found that the
incidence of pain one year following breast cancer mastectomy plus reconstruction was 49% as
compared to 31% for mastectomy alone. This increase was both statistically and clinically
significant, and remains a current undertreated problem. Overall many women develop
persistent pain after breast cancer surgery following either tumor removal or breast
reconstruction. We know that this is influenced by acute pre- and post-surgical pain, but
unfortunately the existing measures available for clinicians to prevent persistent
post-surgical pain are not adequate.
Opioids are commonly used analgesics in the perioperative surgical setting; however, they are
accompanied by significant limitations. Opioids are the most common pharmacologic
intervention used for acute perioperative surgical pain. They are known to decrease pain via
activation of specific receptors (mu, delta, and kappa), which inhibit neuronal firing
resulting in reduced nociceptive activity. Although widely prescribed there are significant
limitations for opioid use including tolerance, addiction, diversion, and even mortality.
There were over 33,000 opioid deaths in the US in 2016 alone and the majority of these have
been from opioid prescriptions. The US is currently experiencing an opioid epidemic wherein
Americans constitute only 5% of the global population yet we consume over 80% of the world's
opioid supply. Unfortunately, while opioids are needed in the surgical setting, the problem
of increased opioid use is itself compounded by surgery. Patients receiving even low-risk
surgeries are 44% more likely to become de novo long-term opioid consumers. With respect to
breast cancer surgery, the odds of developing chronic opioid consumption following mastectomy
increases by approximately 300%. Although the reason(s) for developing chronic opioid
consumption are largely unknown, patients that receive a new opioid prescription within 7
days post-surgery, as compared to those who do not, are more likely to still be receiving
opioids one year out. Thus acute pre-surgical and post-surgical pain, in addition to being
risk factors for persistent chronic pain, may also increase the probability of becoming a
chronic opioid consumer. There is an unmet need for analgesic interventions that are opioid
sparing in the breast cancer surgical setting. This study proposes that acupressure may be
one such option.
Acupressure Self-administered acupressure is one possible safe, self-management technique
which may be effective for improving post-operative pain and opioid consumption. Acupressure,
a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in
which pressure is applied to specific acupoints on the body using a finger or small device,
to treat disease. Prior research has demonstrated that acupressure, self-administered by
women with breast cancer, significantly reduced clinically significant pain by approximately
one-third and was superior to standard therapies. Moreover, these self-rated improvements
were maintained up to one month after treatment was discontinued.
Acupressure has been found to be effective for acute post-surgical pain, but no studies have
examined the impact on the development of chronic pain or acute and chronic opioid use in any
patient population. Four previous studies in diverse patient populations (appendectomy,
cesarean section, gastric cancer, and knee arthroscopy) have found that acupressure delivered
by an acupressure practitioner was able to significantly decrease post-surgical pain compared
to either usual care or sham acupressure from as early as 60 minutes after surgery to as long
as 3 days post-surgery, however no study has measured pain beyond 3 days post-surgery.29-32
As such, it is unknown what impact if any acupressure has on the development of chronic pain
post-surgery. Also, no study has examined the impact of acupressure on either acute or
chronic opioid use. In contrast, the one study that used an acuband (a band worn around the
wrist with a nub over the acupressure point to provide stimulation) at the P6 point commonly
used to treat nausea and vomiting had no impact on post-surgical pain 24 hours after
receiving an appendectomy.
Along with a lack of research on acupressure's impact on chronic pain and opioid use the
impact of this intervention on breast cancer patients undergoing surgery (mastectomy,
lumpectomy, delayed or immediate reconstruction) is unknown. This study is a pilot randomized
clinical trial to explore this intervention in 72 breast cancer patients scheduled for
surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |